LPL Financial LLC Raises Stock Holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD)

LPL Financial LLC raised its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 29.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,391 shares of the company’s stock after acquiring an additional 12,035 shares during the period. LPL Financial LLC owned approximately 0.09% of Lucid Diagnostics worth $44,000 as of its most recent SEC filing.

Separately, Sargent Investment Group LLC purchased a new stake in Lucid Diagnostics during the fourth quarter valued at approximately $442,000. Institutional investors own 74.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on LUCD shares. Cantor Fitzgerald restated an “overweight” rating and set a $2.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, March 26th. Needham & Company LLC reissued a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Friday, April 11th. BTIG Research set a $2.00 price objective on shares of Lucid Diagnostics in a research note on Tuesday, March 25th. Finally, Ascendiant Capital Markets raised their price target on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the stock a “buy” rating in a research note on Monday, April 21st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $3.50.

Lucid Diagnostics Stock Performance

Shares of LUCD stock opened at $1.29 on Friday. The firm has a market cap of $135.94 million, a P/E ratio of -1.13 and a beta of 1.26. The firm’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.10. Lucid Diagnostics Inc. has a one year low of $0.68 and a one year high of $1.80.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.